Artykuły w czasopismach na temat „Bisphosphonate”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Bisphosphonate”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Bergner, R. "Bisphosphonattherapie bei renaler Osteopathie". Osteologie 17, nr 03 (2008): 154–58. http://dx.doi.org/10.1055/s-0037-1619862.
Pełny tekst źródłaAnghelescu, Doralina L., Varayini Pankayatselvan, Rosa Nguyen, Deborah Ward, Jianrong Wu, Huiyun Wu, Denaya D. Edwards i Wayne Furman. "Bisphosphonate Use in Pediatric Oncology for Pain Management". American Journal of Hospice and Palliative Medicine® 36, nr 2 (16.08.2018): 138–42. http://dx.doi.org/10.1177/1049909118793114.
Pełny tekst źródłaKlotz, Christopher, Franz Jakob, Matthias Kohl, Simon von Stengel, Uwe Lange, Friederike Thomasius, Katharina Kerschan-Schindl, Michael Uder i Wolfgang Kemmler. "Effekt von additivem körperlichem Training zur Bisphosphonat-Therapie auf die Knochendichte: Eine systematische Übersichtsarbeit und Meta-Analyse". Osteologie 31, nr 03 (sierpień 2022): 184–94. http://dx.doi.org/10.1055/a-1904-5706.
Pełny tekst źródłaStepaniuk, Kevin. "Bisphosphonate Related Osteonecrosis of the Jaws: A Review". Journal of Veterinary Dentistry 28, nr 4 (grudzień 2011): 277–81. http://dx.doi.org/10.1177/089875641102800413.
Pełny tekst źródłaThirunavukarasu, Ananthi, Hugo Grancho Pinto i Kevin Guy Seymour. "Bisphosphonate and Implant Dentistry – is it Safe?" Primary Dental Journal 4, nr 3 (wrzesień 2015): 30–33. http://dx.doi.org/10.1308/205016815815944650.
Pełny tekst źródłaKawai, Toshiyuki, Kohei Nishitani, Yaichiro Okuzu, Koji Goto, Yutaka Kuroda, Shinichi Kuriyama, Shinichiro Nakamura i Shuichi Matsuda. "Bisphosphonate use is associated with a decreased joint narrowing rate in the non-arthritic hip". Bone & Joint Research 11, nr 11 (1.11.2022): 826–34. http://dx.doi.org/10.1302/2046-3758.1111.bjr-2022-0155.r1.
Pełny tekst źródłaBourrion, Bastien, Cécile Souty, Lucie Fournier, Ana-Maria Vilcu, Thierry Blanchon, Pierre-Yves Böelle, Thomas Hanslik i Mathilde François. "Bisphosphonate Use and Hospitalization for Hip Fractures in Women: An Observational Population-Based Study in France". International Journal of Environmental Research and Public Health 18, nr 16 (20.08.2021): 8780. http://dx.doi.org/10.3390/ijerph18168780.
Pełny tekst źródłaLloyd, Ashley A., Bernd Gludovatz, Christoph Riedel, Emma A. Luengo, Rehan Saiyed, Eric Marty, Dean G. Lorich i in. "Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance". Proceedings of the National Academy of Sciences 114, nr 33 (31.07.2017): 8722–27. http://dx.doi.org/10.1073/pnas.1704460114.
Pełny tekst źródłaNtep, Ntep David Bienvenue, Ernest Kenna, Siafa Antoine Bola i Messanga Charles Bengondo. "The Potential Role of Angiogenic Osteoclast Inhibition in the Occurrence of Bisphosphonate-related Osteonecrosis of the Jaw". Case Reports in Dental Science 1, nr 1 (30.06.2020): 15–21. http://dx.doi.org/10.46619/crds.2020.1-1004.
Pełny tekst źródłaSawatari, Yoh, i Robert E. Marx. "Bisphosphonates and Bisphosphonate Induced Osteonecrosis". Oral and Maxillofacial Surgery Clinics of North America 19, nr 4 (listopad 2007): 487–98. http://dx.doi.org/10.1016/j.coms.2007.07.003.
Pełny tekst źródłaPaskins, Zoe, Fay Crawford-Manning, Elizabeth Cottrell, Nadia Corp, Jenny Wright, Clare Jinks, Simon Bishop i in. "Acceptability of bisphosphonates among patients, clinicians and managers: a systematic review and framework synthesis". BMJ Open 10, nr 11 (listopad 2020): e040634. http://dx.doi.org/10.1136/bmjopen-2020-040634.
Pełny tekst źródłaNeogi, Tuhina, Shanshan Li, Christine Peloquin, Devyani Misra i Yuqing Zhang. "Effect of bisphosphonates on knee replacement surgery". Annals of the Rheumatic Diseases 77, nr 1 (7.10.2017): 92–97. http://dx.doi.org/10.1136/annrheumdis-2017-211811.
Pełny tekst źródłaI, Bashir. "Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures". Journal of Orthopaedics & Bone Disorders 3, nr 2 (2019): 1–8. http://dx.doi.org/10.23880/jobd-16000179.
Pełny tekst źródłaChlebowski, Rowan T., Zhao Chen, Jane A. Cauley, Garnet Anderson, Rebecca J. Rodabough, Anne McTiernan, Dorothy S. Lane i in. "Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women". Journal of Clinical Oncology 28, nr 22 (1.08.2010): 3582–90. http://dx.doi.org/10.1200/jco.2010.28.2095.
Pełny tekst źródłaZhou, Jifang, Karen Sweiss, Edith A. Nutescu, Jin Han, Pritesh R. Patel, Naomi Y. Ko, Todd A. Lee, Brian C. H. Chiu i Gregory S. Calip. "Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare". JCO Oncology Practice 17, nr 3 (marzec 2021): e294-e312. http://dx.doi.org/10.1200/op.20.00479.
Pełny tekst źródłaGnant, Michael, Catherine Van Poznak i Lowell Schnipper. "Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment". American Society of Clinical Oncology Educational Book, nr 37 (maj 2017): 116–22. http://dx.doi.org/10.1200/edbk_177357.
Pełny tekst źródłaBeck, V., E. Solomayer, M. Krimmel, C. Reinert i T. Fehm. "Bisphosphonate-induced osteonecrosis of the jaw: Incidence and risk factors in patients with breast cancer and gynecological malignancies". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 1113. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1113.
Pełny tekst źródłaOkçu, Mehmet, Fatmanur Aybala Koçak, Samet Sancar Kaya i Figen Tuncay. "Is there a familial predisposition to bisphosphonate-induced atypical femoral fractures?" Turkish Journal of Physical Medicine and Rehabilitation 67, nr 3 (1.09.2021): 370–73. http://dx.doi.org/10.5606/tftrd.2021.5248.
Pełny tekst źródłaSapkota, S., S. Baig, T. Hess, A. M. O’Connell, J. Menk, M. Shyne, P. Fazeli, K. Ensrud i A. Shmagel. "Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?" Lupus 29, nr 3 (29.01.2020): 263–72. http://dx.doi.org/10.1177/0961203320903086.
Pełny tekst źródłaMustafa, W., R. O'Byrne, B. Okpaje, A. Gabr, B. Ali, A. Mohamed, S. Cameron i in. "233 BISPHOSPHONATES: ANOTHER COMPLEX DRUG TO PRESCRIBE". Age and Ageing 50, Supplement_3 (listopad 2021): ii9—ii41. http://dx.doi.org/10.1093/ageing/afab219.233.
Pełny tekst źródłaUtari, Tita Ratya, Muhammad Fariez Kurniawan i Shylvia Muchsin Andewa. "<strong>The controlled release profile of risedronate emulgel to inhibit relapse movement in orthodontic treatment</strong>". Padjadjaran Journal of Dentistry 34, nr 1 (9.04.2022): 66. http://dx.doi.org/10.24198/pjd.vol34no1.32628.
Pełny tekst źródłaAtaallah, Basma, Christina Nania i Neel Shah. "PSAT188 Keeping An Eye On Bisphosphonates: Drug Induced Uveitis". Journal of the Endocrine Society 6, Supplement_1 (1.11.2022): A205. http://dx.doi.org/10.1210/jendso/bvac150.421.
Pełny tekst źródłaLicata, Angelo A. "Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates". Annals of Pharmacotherapy 39, nr 4 (kwiecień 2005): 668–77. http://dx.doi.org/10.1345/aph.1e357.
Pełny tekst źródłaGuthrie, Ariane, Kathleen Fairman i Dawn Knudsen Gerber. "Fractured Timelines: Reporting Patterns for Bisphosphonate-Associated Atypical Fractures and Implications for Postmarket Surveillance". Senior Care Pharmacist 37, nr 11 (1.11.2022): 555–64. http://dx.doi.org/10.4140/tcp.n.2022.555.
Pełny tekst źródłaWilkinson, Gregg S., Jacques Baillargeon, Yong-Fang Kuo, Jean L. Freeman i James S. Goodwin. "Atrial Fibrillation and Stroke Associated With Intravenous Bisphosphonate Therapy in Older Patients With Cancer". Journal of Clinical Oncology 28, nr 33 (20.11.2010): 4898–905. http://dx.doi.org/10.1200/jco.2010.28.7524.
Pełny tekst źródłaShalev, Varda, Sarah Sharman Moser, Inbal Goldshtein, Jingbo Yu, Clara Weil, Sophia Ish-Shalom, Vanessa Rouach i Gabriel Chodick. "Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data". Annals of Pharmacotherapy 51, nr 9 (23.05.2017): 757–67. http://dx.doi.org/10.1177/1060028017710482.
Pełny tekst źródłaIto, Kouta, Victoria S. Blinder i Elena B. Elkin. "Cost Effectiveness of Fracture Prevention in Postmenopausal Women Who Receive Aromatase Inhibitors for Early Breast Cancer". Journal of Clinical Oncology 30, nr 13 (1.05.2012): 1468–75. http://dx.doi.org/10.1200/jco.2011.38.7001.
Pełny tekst źródłaHayes, Kaleen N., Elizabeth M. Winter, Suzanne M. Cadarette i Andrea M. Burden. "Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making". Journal of Clinical Medicine 10, nr 5 (9.03.2021): 1140. http://dx.doi.org/10.3390/jcm10051140.
Pełny tekst źródłaWasserzug, Oshri, Israel Kaffe, Towy Sorel Lazarovici, Tal Weissman, Ran Yahalom, Dan M. Fliss i Noam Yarom. "Involvement of the Maxillary Sinus in Bisphosphonate-Related Osteonecrosis of the Jaw: Radiologic Aspects". American Journal of Rhinology & Allergy 31, nr 1 (styczeń 2017): 36–39. http://dx.doi.org/10.2500/ajra.2017.31.4395.
Pełny tekst źródłaArponen, Heidi, Ilkka Vuorimies, Jari Haukka, Helena Valta, Janna Waltimo-Sirén i Outi Mäkitie. "Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates". Journal of Neurosurgery: Pediatrics 15, nr 3 (marzec 2015): 313–20. http://dx.doi.org/10.3171/2014.11.peds14113.
Pełny tekst źródłaVassaki, Maria, Konstantinos E. Papathanasiou, Chrystalleni Hadjicharalambous, Daphne Chandrinou, Petri Turhanen, Duane Choquesillo-Lazarte i Konstantinos D. Demadis. "Self-sacrificial MOFs for ultra-long controlled release of bisphosphonate anti-osteoporotic drugs". Chemical Communications 56, nr 38 (2020): 5166–69. http://dx.doi.org/10.1039/d0cc00439a.
Pełny tekst źródłaPorta-Sales, Josep, Cristina Garzón-Rodríguez, Silvia Llorens-Torromé, Cinzia Brunelli, Alessandra Pigni i Augusto Caraceni. "Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project". Palliative Medicine 31, nr 1 (10.07.2016): 5–25. http://dx.doi.org/10.1177/0269216316639793.
Pełny tekst źródłaGovindarajan, Vaidya, Anthony Diaz, Roberto J. Perez-Roman, S. Shelby Burks, Michael Y. Wang i Allan D. Levi. "Osteoporosis treatment in patients undergoing spinal fusion: a systematic review and meta-analysis". Neurosurgical Focus 50, nr 6 (czerwiec 2021): E9. http://dx.doi.org/10.3171/2021.3.focus2175.
Pełny tekst źródłaCoskun Benlidayi, Ilke, i Rengin Guzel. "Oral Bisphosphonate Related Osteonecrosis of the Jaw: A Challenging Adverse Effect". ISRN Rheumatology 2013 (16.05.2013): 1–6. http://dx.doi.org/10.1155/2013/215034.
Pełny tekst źródłaKim, Hyung Joon, Ha Jin Kim, YunJeong Choi, Moon-Kyoung Bae, Dae Seok Hwang, Sang-Hun Shin i Jae-Yeol Lee. "Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis". International Journal of Molecular Sciences 20, nr 6 (22.03.2019): 1467. http://dx.doi.org/10.3390/ijms20061467.
Pełny tekst źródłaPramanik, Chandrani, Tianda Wang, Sushanta Ghoshal, Lina Niu, Bradley A. Newcomb, Yaodong Liu, Carolyn M. Primus i in. "Microfibrous borate bioactive glass dressing sequesters bone-bound bisphosphonate in the presence of simulated body fluid". Journal of Materials Chemistry B 3, nr 6 (2015): 959–63. http://dx.doi.org/10.1039/c4tb02035a.
Pełny tekst źródłaNanki, Toshihiro, Mai Kawazoe, Kiyoko Uno, Wataru Hirose, Hiroaki Dobashi, Hiroshi Kataoka, Toshihide Mimura, Hiroshi Hagino i Hajime Kono. "Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial". Journal of Clinical Medicine 12, nr 1 (30.12.2022): 292. http://dx.doi.org/10.3390/jcm12010292.
Pełny tekst źródłaRuggiero, Salvatore, Julie Gralow, Robert E. Marx, Ana O. Hoff, Mark M. Schubert, Joseph M. Huryn, Bela Toth, Kathryn Damato i Vicente Valero. "Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer". Journal of Oncology Practice 2, nr 1 (styczeń 2006): 7–14. http://dx.doi.org/10.1200/jop.2006.2.1.7.
Pełny tekst źródłaSchöffel, D. "Wirkung von Bisphophonaten auf Osteoporoseschmerzen". Osteologie 17, nr 04 (2008): 219–21. http://dx.doi.org/10.1055/s-0037-1619870.
Pełny tekst źródłaWalia, Manpreet S., Saryu Arora i Bhawana Singal. "Jaw Osteonecrosis a Risk Factor in Bisphosphonate Therapy - A Dental Concern". Journal of Oral Health and Community Dentistry 4, nr 3 (2010): 72–77. http://dx.doi.org/10.5005/johcd-4-3-72.
Pełny tekst źródłaErdem, Yusuf, Zafer Atbasi, Tuluhan Yunus Emre, Gülis Kavadar i Bahtiyar Demiralp. "Effect of Long-Term Use of Bisphosphonates on Forearm Bone: Atypical Ulna Fractures in Elderly Woman with Osteoporosis". Case Reports in Orthopedics 2016 (2016): 1–4. http://dx.doi.org/10.1155/2016/4185202.
Pełny tekst źródłaOteri, Giacomo, Ennio Bramanti, Valentina Nigrone i Marco Cicciù. "Decayed, Missing, and Filled Teeth Index and Periodontal Health in Osteoporotic Patients Affected by BRONJ: An Observational Study". Journal of Osteoporosis 2013 (2013): 1–7. http://dx.doi.org/10.1155/2013/231289.
Pełny tekst źródłaNewcomb, Polly A., Michael N. Passarelli, Amanda I. Phipps, Garnet L. Anderson, Jean Wactawski-Wende, Gloria Y. F. Ho, Mary Jo O'Sullivan i Rowan T. Chlebowski. "Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer". Journal of Clinical Oncology 33, nr 10 (1.04.2015): 1186–90. http://dx.doi.org/10.1200/jco.2014.58.6842.
Pełny tekst źródłaFAVIA, GIANFRANCO, GIOVANNI PIETRO PILOLLI i EUGENIO MAIORANO. "Osteonecrosis of the Jaw Correlated to Bisphosphonate Therapy in Non-oncologic Patients: Clinicopathological Features of 24 Patients". Journal of Rheumatology 36, nr 12 (2.11.2009): 2780–87. http://dx.doi.org/10.3899/jrheum.090455.
Pełny tekst źródłaKirpichnikov, M. V., V. V. Podolsky, E. N. Yarygina, A. S. Serbin i K. A. Aleshanov. "Care and management of bisphosphonate-associated osteonecrosis of jaw in patient with pathological fracture of mandible: case study". Medical alphabet 3, nr 23 (21.11.2019): 34–36. http://dx.doi.org/10.33667/2078-5631-2019-3-23(398)-34-36.
Pełny tekst źródłaEbzeev, A. K. "Bisphosphonate-related osteonecrosis of the jaw (BRONJ) in cancer patients". Kazan medical journal 101, nr 2 (13.04.2020): 226–31. http://dx.doi.org/10.17816/kmj2020-226.
Pełny tekst źródłaWellman, Samuel S., David E. Attarian i Jordan F. Schaeffer. "Periprosthetic Femoral Insufficiency Fracture in a Patient on Long-term Bisphosphonate Therapy". Duke Orthopaedic Journal 2, nr 1 (2012): 66–69. http://dx.doi.org/10.5005/jp-journals-10017-1021.
Pełny tekst źródłaAlQarooni, Sayed Hashim, Ugo Ruggiero i Sri Priya Suresh. "Atypical fractures secondary to bisphosphonate therapy: A case series and pictorial review". Indian Journal of Musculoskeletal Radiology 3 (30.06.2021): 45–53. http://dx.doi.org/10.25259/ijmsr_2_2021.
Pełny tekst źródłaYang, Yan-Li, Zi-Jian Xiang, Jing-Hua Yang, Wen-Jie Wang i Ruo-Lan Xiang. "The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis". Therapeutic Advances in Medical Oncology 11 (styczeń 2019): 175883591985523. http://dx.doi.org/10.1177/1758835919855235.
Pełny tekst źródłaStevenson, Matt D., Jeremy E. Oakley, Myfawny Lloyd Jones, Alan Brennan, Juliet E. Compston, Eugene V. McCloskey i Peter L. Selby. "The Cost-Effectiveness of an RCT to Establish Whether 5 or 10 Years of Bisphosphonate Treatment Is the Better Duration for Women With a Prior Fracture". Medical Decision Making 29, nr 6 (9.06.2009): 678–89. http://dx.doi.org/10.1177/0272989x09336077.
Pełny tekst źródła